Hemostasis News and Research

RSS

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.

FDA approves Tenaxis Medical’s ArterX Surgical Sealant

Tenaxis Medical, Inc., a medical device company focused on the development of functionally designed surgical sealants has received FDA approval to bring its innovative ArterX Surgical Sealant to the market.

4 Mar 2013

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).

1 Mar 2013

Epic Wound Care enters beta test agreement with Ryan Network for UEEC's hemostatic gauze

United Health Products, Inc.'s www.unitedhealthproductsinc.com wholly owned subsidiary, Epic Wound Care, Inc., which develops and markets products and technologies in the healthcare sector, is pleased to announce that it has entered into a beta test agreement with the distinguished Ryan Network for UEEC's hemostatic gauze. The gauze is registered and branded in the USA under the trademark HemoStyp.

15 Feb 2013

FDA approves Cardiva Medical's VASCADE Vascular Closure System

Cardiva Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the VASCADE Vascular Closure System (VCS).

6 Feb 2013

DFG again approves funding for Mainz University to promote cardiovascular research

The German Research Foundation (DFG) has again approved funding for the Department of Internal Medicine II of the Mainz University Medical Center to promote cardiovascular research - for the second time within only a few weeks.

30 Jan 2013

Sanofi introduces LeGoo gel to temporarily stop blood flow during cardiovascular surgery

Sanofi US announced the commercial launch of LeGoo, a biopolymer gel that allows surgeons to temporarily stop blood flow during surgery without the use of clamps, elastic loops or other conventional occlusion devices, which may increase risk of trauma to blood vessels.

30 Jan 2013

German Research Foundation approves funding for Mainz study on cardiovascular disorders

The German Research Foundation has approved funding for the Department of Internal Medicine II of the Mainz University Medical Center to promote the further study of the interrelations between the immune system and cardiovascular system disorders.

29 Jan 2013

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

2 Jan 2013

Fibrinogen could bypass intraoperative transfusion needs

Giving fibrinogen as first-line treatment for intraoperative bleeding could reduce the need for blood transfusion, shows a small randomized controlled trial.

2 Jan 2013

Novo Nordisk launches HemaGo mobile app to help individuals with hemophilia

Novo Nordisk announced today the introduction of HemaGo, a mobile application (app) to help individuals with hemophilia and their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact of hemophilia on life events.

From Novo Nordisk 28 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

Haemonetics second quarter 2013 net revenue increases 22% to $218.2 million

Haemonetics Corporation today reported second quarter 2013 net revenue of $218.2 million, up 22%, GAAP net income of $6.5 million, down 53%, and diluted earnings per share of $0.25, down 53%.

29 Oct 2012

Study finds decline in inpatient mortality rate for upper gastrointestinal hemorrhage in the U.S.

The number of patients dying from upper gastrointestinal bleeding has decreased over the past two decades, a result researchers attribute to the advances in medical and endoscopic therapies introduced over the past 20 years, according to a report unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

24 Oct 2012

U of U researchers receive NIH grant to study cellular and molecular causes of blood clots

University of Utah Department of Medicine researchers have received $16 million from the National Institutes of Health (NIH) to set up a translational research center to study the cellular and molecular causes of blood clots, a serious threat to millions of people who have diabetes, are obese or have other metabolic disorders.

15 Aug 2012

EEA stapler offers hemostasis advantage over PPH

The EEA stapler may have benefits over the PPH stapler for circular stapled hemorrhoidopexy, the results of the first head-to-head study of the devices show.

1 Aug 2012

T2Hemostasis provides reliable and rapid results when compared to conventional systems

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of new data on hemostasis monitoring at the American Association for Clinical Chemistry Annual Meeting, July 15-19, 2012, in Los Angeles, CA.

20 Jul 2012

IL announces worldwide launch of ACL TOP 300 CTS Hemostasis Testing System

Instrumentation Laboratory (IL), today, announced the worldwide commercial launch of the ACL TOP 300 CTS Hemostasis Testing System, as the newest member of the ACL TOP Family. Ideally suited for processing 50-100 patient samples per day, the ACL TOP 300 CTS offers full Testing Process Automation for low-to-medium-volume, routine or specialty Hemostasis laboratories or as an adjunct to other installed ACL TOP systems.

9 Jul 2012

TMC receives NIH grant to evaluate pepducin in heart disease patients

Tufts Medical Center researchers are developing a first-of-its-kind drug to prevent deadly blood clots in heart disease patients, without the risk of serious bleeding associated with current medications. The National Heart, Lung, and Blood Institute of the National Institutes of Health has just awarded the team led by Athan Kuliopulos, MD, PhD, a $10 million grant to start testing a drug based on this novel technology.

4 Jul 2012

T2Endotoxin assay extends reach of T2MR detection

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on endotoxin detection at the American Society for Microbiology General Meeting, June 16-19, 2012, in San Francisco, CA.

18 Jun 2012

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

8 Jun 2012